Serplulimab
- Generic Name
- Serplulimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2231029-82-4
- Unique Ingredient Identifier
- S3GQZ2K36V
- Indication
用于经过标准治疗失败的、不可切除或转移性高度微卫星不稳定型（MSI-H）成人晚期实体瘤患者。
- Associated Conditions
- -
- Associated Therapies
- -
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 109
- Registration Number
- NCT06394661
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06368141
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- The Central Hospital of Lishui City
- Target Recruit Count
- 56
- Registration Number
- NCT06364046
- Locations
- 🇨🇳
Lishui central hospital, Lishui, Zhejiang, China
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 50
- Registration Number
- NCT06354218
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06350162
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06334757
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Serplulimab Combined With CCRT for LS-SCLC.
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06295926
- Locations
- 🇨🇳
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT06280495
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06195683
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 114
- Registration Number
- NCT05975749
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.